Top Markets
Coin of the day
Diagnocure, Inc. Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Pozycja w akcjach #41417
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Cena akcji
$0.0001
Ostatnia synchronizacja: 2025-06-11
Kapitalizacja rynkowa
$21.52K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel Diagnocure, Inc. (DGCRF)

Kategoria

Zyski dla Diagnocure, Inc. (DGCRF)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Diagnocure, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Diagnocure, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów